Wcn24-1163 Treatment Goals From the Perspective of Immunoglobulin a Nephropathy Patients - Results From a Real-World Study

Immunoglobulin A nephropathy (IgAN) is a rare disease with an estimated annual incidence of 25 per million worldwide. Approximately 50% of IgAN patients with proteinuria ≥1 g/day progress to kidney failure in 15 years. Limited data is available on treatment goals among patients with IgAN in the real-world setting and this analysis aims to close this gap.